Skip to main content

Nutritional therapy in autosomal dominant polycystic kidney disease

Journal of Nephrology volume 31, pages 635–643 (2018)Cite this article

Abstract

CKD-related nutritional therapy (NT) is a crucial cornerstone of CKD patients’ treatment, but the role of NT has not been clearly investigated in autosomal dominant polycystic kidney disease (ADPKD). Several clinical studies have focused on new pharmacological approaches to delay cystic disease progression, but there are no data on dietary interventions in ADPKD patients. The aim of this paper is to analyze the evidence from the literature on the impact of five nutritional aspects (water, sodium, phosphorus, protein intake, and net acid load) in CKD-related ADPKD extrapolating—where information is unavailable—from what occurs in CKD non-ADPKD patients Sodium intake restriction could be useful in decreasing the growth rate of cysts. Although further evidence is needed, restriction of phosphorus and protein intake restriction represent cornerstones of the dietary support of renal non-ADPKD patients and common sense can guide their use. It could be also helpful to limit animal protein, increasing fruit and vegetables intake together with a full correction of metabolic acidosis. Finally, fluid intake may be recommended in the early stages of the disease, although it is not to be prescribed in the presence of moderate to severe reduction of renal function.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

USD 39.95

Price includes VAT (USA)
Tax calculation will be finalised during checkout.

Fig. 1
Fig. 2
Fig. 3
Fig. 4

References

  1. Liut F, Izzi C, Dallera N, Scolari F (2017) ADPKD e cuore. G Ital Nefrol 34(Suppl 69):119–130

    PubMed  Google Scholar 

  2. Churchill DN, Bear JC, Morgan J, Payne RH, McManamon PJ, Gault MH (1984) Prognosis of adult onset polycystic kidney disease re-evaluated. Kidney Int 26:190–193

    CAS  Article  Google Scholar 

  3. Yamaguchi T, Nagao S, Wallace DP, Belibi FA, Cowley BD, Pelling JC, Grantham JJ (2003) Cyclic AMP activates B-Raf and ERK in cyst epithelial cells from autosomal-dominant poly- cystic kidneys. Kidney Int 63:1983–1994

    CAS  Article  Google Scholar 

  4. Yamaguchi T, Wallace DP, Magenheimer BS, Hempson SJ, Grantham JJ, Calvet JP (2004) Calcium restriction allows cAMP activation of the B-Raf/ERK pathway, switching cells to a cAMP-dependent growth-stimulated phenotype. J Biol Chem 279:40419–40430

    CAS  Article  Google Scholar 

  5. Gattone VH 2nd, Wang X, Harris PC, Torres VE (2003) Inhibition of renal cystic disease development and progression by a vasopressin V2 receptor antagonist. Nat Med 9:1323–1326

    CAS  Article  Google Scholar 

  6. Yamaguchi T, Nagao S, Kasahara M, Takahashi H, Grantham JJ (1997) Renal accumulation and excretion of cyclic adenosine monophosphate in a murine model of slowly progressive polycystic kidney disease. Am J Kidney Dis 30:703–709

    CAS  Article  Google Scholar 

  7. Nagao S (2006) Increased Water intake decreases progression of polycystic kidney disease in the PCK rat. J Am Soc Nephrol 17:2220–2227

    CAS  Article  Google Scholar 

  8. Hopp K, Wang X, Ye H, Irazabal MV, Harris PC, Torres VE (2015) Effects of hydration in rats and mice with polycystic kidney disease. Am J Physiol Renal Physiol 308(3):F261–F266

    CAS  Article  Google Scholar 

  9. Barash I, Ponda MP, Goldfarb DS, Skolnik EY (2010) A pilot clinical study to evaluate changes in urine osmolality and urine camp in response to acute and chronic water loading in autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol 5:693–697

    CAS  Article  Google Scholar 

  10. Higashihara E, Kikuo Nutahara K, Tanbo M, Hara H, Miyazaki I, Kobayashi H, Nitatori T (2014) Does increased water intake prevent disease progression in autosomal dominant polycystic kidney disease? Nephrol Dial Transplant 29:1710–1719

    CAS  Article  Google Scholar 

  11. Amro OW, Paulus JK, Noubary F, Perrone RD (2016) Low-osmolar diet and adjusted water intake for vasopressin reduction in autosomal dominant polycystic kidney disease: a pilot randomized controlled trial. AM J Kidney Dis 68:882–891

    CAS  Article  Google Scholar 

  12. El-Damanawi R, Harris T, Sandford RN, Karet Frankl FE, Hiemstra TF (2017) Patient survey of current water Intake practices in autosomal dominant Polycystic kidney disease: the SIPs survey. Clin Kidney J 10:305–309

    Article  Google Scholar 

  13. Taylor JM, Hamilton-Reeves JM, Sullivan DK, Gibson CA, Creed C, Carlson SE, Wesson DE, Grantham JJ (2017) Diet and polycystic kidney disease: a pilot intervention study. Clin Nutr 36(2):458–466

    CAS  Article  Google Scholar 

  14. Wang CJ, Grantham JJ, Wetmore JB (2013) The medicinal use of water in renal disease. Kidney Int 84:45–53

    Article  Google Scholar 

  15. Clark WF, Sontrop JM, Huang SH, Moist L, Bouby N, Bankir L (2016) Hydration and chronic kidney disease progression: a critical review of the evidence. Am J Nephrol 43:281–292

    CAS  Article  Google Scholar 

  16. Torres VE, Chapman AB, Devuyst O, Gansevoort RT, Grantham JJ, Higashihara E, Perrone RD, Krasa HB, Ouyang J, Czerwiec FS; TEMPO 3:4 Trial Investigators (2012) Tolvaptan in patients with autosomal dominant polycystic kidney disease. N Engl J Med 367(25):2407–2418

    CAS  Article  Google Scholar 

  17. Gansevoort RT, Arici M, Benzing T, Birn H, Capasso G, Covic A, Devuyst O, Drechsler C, Eckardt KU, Emma F, Knebelmann B, Le Meur Y, Massy ZA, Ong AC, Ortiz A, Schaefer F, Torra R, Vanholder R, Więcek A, Zoccali C, Van Biesen W (2016). Recommendations for the use of tolvaptan in autosomal dominant polycystic kidney disease: a position statement on behalf of the ERA-EDTA Working Groups on Inherited Kidney Disorders and European Renal Best Practice. Nephrol Dial Transplant 31(3):337–348

    Article  Google Scholar 

  18. Chapman AB, Torres VE, Perrone RD, Steinman TI, Bae KT, Miller JP, Miskulin DC, Rahbari Oskoui F, Masoumi A, Hogan MC, Winklhofer FT, Braun W, Thompson PA, Meyers CM, Kelleher C, Schrier RW (2010) HALT T polycystic kidney disease trials: design and implementation. Clin J Am Soc Nephrol 5(1):102–109

    Article  Google Scholar 

  19. Torres VE, Abebe KZ, Schrier RW, Perrone RD, Chapman AB, Yu AS, Braun WE, Steinman TI, Brosnahan G, Hogan MC, Rahbari FF, Grantham JJ, Bae KT, Moore CG, Flessner MF (2017) Dietary salt restriction is beneficial to the management of autosomal dominant polycystic kidney disease. Kidney Int 91(2):493–500

    CAS  Article  Google Scholar 

  20. Taylor JM, Ptomey L, Hamilton-Reeves JM, Sullivan DK, Creed C, Carlson SE, Wesson DE, Grantham JJ, Gibson CA (2016) Experiences and perspectives of polycystic kidney disease patients following a diet of reduced osmoles, protein, and acid precursors supplemented with water: a qualitative study. PLoS One 11(8):e0161043

    Article  Google Scholar 

  21. Rebholz CM, Crews DC, Grams ME, Steffen LM, Levey AS, Miller ER 3rd, Appel LJ, Coresh J (2016) DASH (dietary approaches to stop hypertension) diet and risk of subsequent kidney disease. Am J Kidney Dis 68(6):853–861

    Article  Google Scholar 

  22. Nomura K, Asayama K, Jacobs L, Thijs L, Staessen JA (2017) Renal function in relation to sodium intake: a quantitative review of the literature. Kidney Int 92(1):67–78

    CAS  Article  Google Scholar 

  23. Tonelli M, Sacks F, Pfeffer M, Gao Z, Curhan G; Cholesterol And Recurrent Events Trial Investigators (2005) Relation between serum phosphate level and cardiovascular event rate in people with coronary disease. Circulation 112(17):2627–2633

    CAS  Article  Google Scholar 

  24. Chang AR, Lazo M, Appel LJ, Gutiérrez OM, Grams ME (2014) High dietary phosphorus intake is associated with all-cause mortality: results from NHANES III. Am J Clin Nutr 99(2):320–327

    CAS  Article  Google Scholar 

  25. Gutiérrez OM (2013) The connection between dietary phosphorus, cardiovascular disease, and mortality: where we stand and what we need to know. Adv Nutr. 4(6):723–729

    Article  Google Scholar 

  26. Tonelli M (2013) Serum phosphorus in people with chronic kidney disease: you are what you eat. Kidney Int 84(5):871–873

    CAS  Article  Google Scholar 

  27. O’Seaghdha CM, Hwang SJ, Muntner P, Melamed ML, Fox CS (2011) Serum phosphorus predicts incident chronic kidney disease and end-stage renal disease. Nephrol Dial Transplant 26(9):2885–2890

    Article  Google Scholar 

  28. De Rechter S, Bacchetta J, Godefroid N, Dubourg L, Cochat P, Maquet J, Raes A, De Schepper J, Vermeersch P, Van Dyck M, Levtchenko E, D’Haese P, Evenepoel P, Mekahli D (2017) Evidence for bone and mineral metabolism alterations in children with autosomal dominant polycystic kidney disease. J Clin Endocrinol Metab 102(11):4210–4217

    Article  Google Scholar 

  29. Di Iorio B, Molony D, Bell C, Cucciniello E, Bellizzi V, Russo D, Bellasi A; INDEPENDENT Study Investigators (2013) Sevelamer versus calcium carbonate in incident hemodialysis patients: results of an open-label 24-month randomized clinical trial. Am J Kidney Dis 62(4):771–778

    Article  Google Scholar 

  30. Di Iorio B, Bellasi A, Russo D; INDEPENDENT Study Investigators (2012) Mortality in kidney disease patients treated with phosphate binders: a randomized study. Clin J Am Soc Nephrol. 7(3):487–493

    Article  Google Scholar 

  31. Pérez-Torres A, González Garcia ME, San José-Valiente B, Bajo Rubio MA, Celadilla Diez O, López-Sobaler AM, Selgas R (2017) Protein-energy wasting syndrome in advanced chronic kidney disease: prevalence and specific clinical characteristics. Nefrologia Jul 26. pii:S0211–6995(17)30141-8. https://doi.org/10.1016/j.nefro.2017.06.004 [Epub ahead of print]

    Article  Google Scholar 

  32. Cupisti A, D’Alessandro C, Finato V, Del Corso C, Catania B, Caselli GM, Egidi MF (2017) Assessment of physical activity, capacity and nutritional status in elderly peritoneal dialysis patients. BMC Nephrol 18(1):180

    Article  Google Scholar 

  33. Aukema HM, Ogborn MR, Tomobe K, Takahashi H, Hibino T, Holub BJ. (1992) Effects of dietary protein restriction and oil type on the early progression of murine polycystic kidney disease. Kidney Int. 42(4):837–842

    CAS  Article  Google Scholar 

  34. Aukema HM, Housini I, Rawling JM (1999) Dietary soy protein effects on inherited polycystic kidney disease are influenced by gender and protein level. J Am Soc Nephrol 10(2):300–308

    CAS  PubMed  Google Scholar 

  35. Tomobe K, Philbrick D, Aukema HM, Clark WF, Ogborn MR, Parbtani A, Takahashi H, Holub BJ (1994) Early dietary protein restriction slows disease progression and lengthens survival in mice with polycystic kidney disease. J Am Soc Nephrol 5(6):1355–1360

    CAS  PubMed  Google Scholar 

  36. Barsotti G, Cupisti A, Moriconi L, Cozza V, Falbo E, Gattai V, Pozzolini L, Meola M (1995) Effects of reduced protein intake in rats with congenital polycystic kidney without renal failure. Contrib Nephrol 115:137–140

    Article  Google Scholar 

  37. Ogborn MR, Nitschmann E, Weiler HA, Bankovic-Calic N (2000) Modification of polycystic kidney disease and fatty acid status by soy protein diet. Kidney Int 57(1):159–166

    CAS  Article  Google Scholar 

  38. Yamaguchi T, Devassy JG, Monirujjaman M, Gabbs M, Aukema HM (2016) Lack of Benefit of early intervention with dietary flax and fish oil and soy protein in orthologous rodent models of human hereditary polycystic kidney disease. PLoS One 11(5):e0155790

    Article  Google Scholar 

  39. Warner G, Hein KZ, Nin V, Edwards M, Chini CC, Hopp K, Harris PC, Torres VE, Chini EN (2016) Food restriction ameliorates the development of polycystic kidney disease. J Am Soc Nephrol 27(5):1437–1447

    CAS  Article  Google Scholar 

  40. Kipp KR, Rezaei M, Lin L, Dewey EC, Weimbs T (2016) A mild reduction of food intake slows disease progression in an orthologous mouse model of polycystic kidney disease. Am J Physiol Renal Physiol 310(8):F726-F731

    Article  Google Scholar 

  41. Peng CY, Sankaran D, Ogborn MR, Aukema HM (2009) Dietary soy protein selectively reduces renal prostanoids and cyclooxygenases in polycystic kidney disease. Exp Biol Med (Maywood) 234(7):737–743

    CAS  Article  Google Scholar 

  42. Klahr S, Breyer JA, Beck GJ, Dennis VW, Hartman JA, Roth D, Steinman TI, Wang SR, Yamamoto ME (1995) Dietary protein restriction, blood pressure control, and the progression of polycystic kidney disease. Modification of Diet in Renal Disease Study Group. J Am Soc Nephrol 5(12)2037–2034

    CAS  PubMed  Google Scholar 

  43. Choukroun G, Itakura Y, Albouze G, Christophe JL, Man NK, Grünfeld JP, Jungers P (1995) Factors influencing progression of renal failure in autosomal dominant polycystic kidney disease. J Am Soc Nephrol 6(6):1634–1642

    CAS  PubMed  Google Scholar 

  44. Yamamoto J, Nishio S, Hattanda F, Nakazawa D, Kimura T, Sata M, Makita M, Ishikawa Y, Atsumi T (2017) Branched-chain amino acids enhance cyst development in autosomal dominant polycystic kidney disease. Kidney Int 92(2):377–387

    CAS  Article  Google Scholar 

  45. Di Iorio BR, Di Micco L, Marzocco S, De Simone E, De Blasio A, Sirico ML, Nardone L, On Behalf Of Ubi Study Group (2017) Very low-protein diet (VLPD) reduces metabolic acidosis in subjects with chronic kidney disease: the “Nutritional Light Signal” of the Renal Acid Load. Nutrients 9(1)

  46. Goraya N, Simoni J, Jo CH, Wesson DE. (2013) A comparison of treating metabolic acidosis in CKD stage 4 hypertensive kidney disease with fruits and vegetables or sodium bicarbonate. Clin J Am Soc Nephrol. 8(3):371–381

    CAS  Article  Google Scholar 

  47. Goraya N, Wesson DE (2013) Does correction of metabolic acidosis slow chronic kidney disease progression? Curr Opin Nephrol Hypertens 22(2):193–197

    CAS  Article  Google Scholar 

  48. Bissler JJ. (2015) Therapies for polycystic kidney disease. Curr Opin Pediatr. 27(2):227–232

    CAS  Article  Google Scholar 

  49. Di Iorio B, Aucella F, Conte G, Cupisti A, Santoro D (2012) A prospective, multicenter, randomized, controlled study: the correction of metabolic acidosis with use of bicarbonate in Chronic Renal Insufficiency (UBI) Study. J Nephrol. 25(3):437–440

    Article  Google Scholar 

  50. Remer T, Manz F (1994) Estimation of the renal net acid excretion by adults consuming diets containing variable amounts of protein. Am J Clin Nutr 59:1356–1361

    CAS  Article  Google Scholar 

  51. Frassetto LA, Todd KM, Morris RJC, Sebastian A (1998) Estimation of net endogenous noncarbonic acid production in humans from diet potassium and protein contents. Am J Clin Nutr 68:576–583

    CAS  Article  Google Scholar 

  52. Tanner GA (1998) Potassium citrate/citric acid intake improves renal function in rats with polycystic kidney disease. J Am Soc Nephrol 9(7):1242–1248

    CAS  PubMed  Google Scholar 

  53. Torres VE, Keith DS, Offord KP, Kon SP, Wilson DM (1994) Renal ammonia in autosomal dominant polycystic kidney disease. Kidney Int 45(6):1745–1753

    CAS  Article  Google Scholar 

  54. D’Alessandro C, Piccoli GB, Calella P, Brunori G, Pasticci F, Egidi MF, Capizzi I, Bellizzi V, Cupisti A (2016) “Dietaly”: practical issues for the nutritional management of CKD patients in Italy. BMC Nephrol 17(1):102

    Article  Google Scholar 

  55. Magistroni R, Boletta A (2017) Defective glycolysis and the use of 2-deoxy-D-glucose in polycystic kidney disease: from animal models to humans. J Nephrol 30(4):511–519

    CAS  Article  Google Scholar 

  56. Girardat-Rotar L, Puhan MA, Braun J, Serra AL. (2017).Long-term effect of coffee consumption on autosomal dominant polycystic kidneys disease progression: results from the Suisse ADPKD, a Prospective Longitudinal Cohort Study. J Nephrol. https://doi.org/10.1007/s40620-017-0396-8

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. U.O.C. di Nefrologia, PO “Agostino Landolfi”, Via Melito snc, 83029, Solofra, AV, Italy

    Biagio R. Di Iorio

  2. Department of Clinical and Experimental Medicine, University of Pisa, 56126, Pisa, Italy

    Adamasco Cupisti & Claudia D’Alessandro

  3. U.O.C. di Nefrologia, Dialisi, Ospedale Sant’Anna-Como, ASST-Lariana, Como, Italy

    Antonio Bellasi

  4. Department of Nephrology and Dialysis, Parodi, Delfino Hospital, Colleferro, Italy

    Vincenzo Barbera & Luca Di Lullo

Authors
  1. Biagio R. Di Iorio
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Adamasco Cupisti
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Claudia D’Alessandro
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Antonio Bellasi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Vincenzo Barbera
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Luca Di Lullo
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Biagio R. Di Iorio.

Ethics declarations

Conflict of interest

On behalf of all authors, the corresponding author states that there is no conflict of interest.

Ethical approval

All procedures performed in this study were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Di Iorio, B.R., Cupisti, A., D’Alessandro, C. et al. Nutritional therapy in autosomal dominant polycystic kidney disease. J Nephrol 31, 635–643 (2018). https://doi.org/10.1007/s40620-018-0470-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40620-018-0470-x

Keywords

  • ADPKD
  • CKD
  • Nutritional therapy
  • Fluid intake
  • Sodium intake
  • Protein intake
  • Phosphorus intake
  • Metabolic acidosis